Background: Autism spectrum disorders (ASD) are early onset conditions characterized by significant impairment in social interaction and communication.

Background: Personality factors have always been considered to play an important role in the etiology of substance-related disorders. Psychopathologic factors underlying an individual's personality structure have a major role in his or her tendency to use substances. This comorbidity can have an adverse effect on seeking and complying with treatment. Objective: This review provides the comorbidity of personality disorders and substance use disorders (SUD). Methods: In this report which was conducted in 2016, authors gathered data from different journals issued in print or electronic versions. These journals were indexed in Web of Science (Thomson Reuters), PubMed, Scopus, Google Scholar, ProQuest, Science Direct, Scientific Information Database (SID) and Magiran. A comprehensive search was done using keywords "Comorbidity", "Personality disorders" and "Substance use disorders". The research investigated in this review was conducted from January 1995 to 2016. Results: Comorbidity of borderline personality disorder, antisocial personality and diagnostic and therapeutic considerations are the most well-known problems in personality disorder. In dealing with these patients special attention should be paid to their safety, suicidal and homicidal thoughts Conclusion: It should be noted that an early diagnosis of comorbid personality disorder would lead to an adjusted expectancy from treatment, and adoption of long-term treatments for these patients

Smoking habits are common in schizophrenic patients. Nicotine can suppress negative symptoms and cognitive impairments. The aim of this study was to determine the efficacy of bupropion on cognitive function in schizophrenic patients. This study is a double blind randomized controlled trial in a large referral psychiatric university hospital in Iran. Ninety smoker schizophrenic patients were randomly allocated (based on DSM -IV TR criteria) in two groups (46 patients for case group and 44 patients in control group). They get risperidone up to 6 mg/d and bupropion up to 400 mg/d .clinical assessment (Positive and Negative Syndrome Scale (PANSS), Brief psychiatric rating scale (BPRS) were taken in beginning of study, 14 th and 28 th days of study. Cognitive assessment (Stroop, Digit Span, and Wechsler, Wisconsin) were taken in begging of study, the days 2 nd , 7 th , 14 th , 28 th . All data were analyzed by SPSS Ver. 17 with analytic and descriptive tests. Mean age of patients was 37.66±1.01. Mean duration of disorder was 11.63±.98 years. The scores were significantly lower at the day 28 th compared to the beginning of the study in both groups in Wechsler, Stroop color word , Stroop word , Stroop color , BPRS, PANSS p value ≤0.05 .The difference between the two treatments was not significant as indicated by the effect of group, the between-subjects factor p value ≥0.05. In this study, the side effects were examined and there was no significant difference between the two groups p value ≥0.05. Augmentation of bupropion to routine treatment improves cognitive symptoms of schizophrenia in abstinence of tobacco.